Activated T cells armed with bispecific antibodies kill tumor targets

Current Opinion in Hematology

Volumn 22, Issue 6, 2015, Pages 476-483

  Bhutani, Divaya ^a,c   Lum, Lawrence G ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Activated T cells; Adoptive T cell therapy; Bispecific antibodies

Indexed keywords

BISPECIFIC ANTIBODY; BLINATUMOMAB; CATUMAXOMAB; CHIMERIC ANTIGEN RECEPTOR; ERTUMAXOMAB; IPILIMUMAB; PEMBROLIZUMAB; TUMOR ANTIGEN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ANTIGEN BINDING; BINDING AFFINITY; BREAST CANCER; CANCER IMMUNIZATION; CANCER PATIENT; CYTOTOXIC T LYMPHOCYTE; DISEASE CLEARANCE; DISEASE SEVERITY; DRUG EFFICACY; ENZYME INHIBITION; HUMAN; NEOPLASM; NONHODGKIN LYMPHOMA; OVARY CANCER; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; STOMACH CANCER; T LYMPHOCYTE; TREATMENT RESPONSE; UMBILICAL CORD BLOOD; CYTOLOGY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; NEOPLASMS; PATHOLOGY;

ANTIBODIES, BISPECIFIC; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; NEOPLASMS; T-LYMPHOCYTES;

EID: 84944072257     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0000000000000176     Document Type: Review

References (56)

1. Signori A, Crocchiolo R, Oneto R, et al. Chronic GVHD is associated with lower relapse risk irrespective of stem cell source among patients receiving transplantation from unrelated donors. Bone Marrow Transplant 2012; 47:1474-1478.
2. Baron F, Maris MB, Sandmaier BM, et al. Graft versus tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 2005; 23:1993-2003.
3. Deol A, Lum LG. Role of donor lymphocyte infusions in relapsed haematological malignancies after stem cell transplantation revisited. Cancer Treat Rev 2010; 36:528-538.
4. Kolb HJ, Holler E. Adoptive immunotherapy with donor lymphocyte transfusions. Curr Opin Oncol 1997; 9:139-145.
5. Rosenberg SA, Spiess P, Lafreniere R, et al. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986; 233:1318-1321.
6. Noonan KA, Huff CA1, Davis J, et al. Adoptive transfer of activated marrowinfiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma. Sci Transl Med 2015; 7:288ra78.
7. Ueda M, Joshi ID, Dan M, et al. Preclinical studies for adoptive immunotherapy in bone marrow transplantation, II: generation of anti-CD3 activated cytotoxic T cells from normal donors and autologous bone marrow transplant candidates. Transplantation 1993; 56:351-356.
8. Lum LG, LeFever AV, Treisman JS, et al. Immune modulation in cancer patients after adoptive transfer of anti-CD3/anti-CD28-costimulated T cells: phase I clinical trial. J Immunother 2001; 24:408-419.
9. Sadelain M, Brentjens R, Riviè re I, et al. The basic principles of chimeric antigen receptor design. Cancer Discov 2013; 3:388-398.
10. Curran KJ, Pegram HJ, Brentjens RJ, et al. Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. J Gene Med 2012; 14:405-415.
11. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368:1509-1518.
12. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371:1507-1517.
13. Kochenderfer JN, Dudley ME, Carpenter RO, et al. Donor-derived CD19- Targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 2013; 122:4129-4139.
14. Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2015; 33:540-549.
15. Suerth JD, Schambach A, Baum C, et al. Genetic modification of lymphocytes by retrovirus-based vectors. Curr Opin Immunol 2012; 24:598-608.
16. Raso V, Griffin T. Hybrid antibody with dual specificity for the delivery of ricin to immunoglobin bearing target cells. Cancer Res 1981; 41:2073-2078.
17. Kontermann RE, Brinkmann U. Bispecific antibodies. Drug Discov Today 2015; pii:S1359-S6446.
18. Zeidler R, Mysliwietz J, Csánady M, et al. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 2000; 83:261-266.
19. Löffler A, Kufer P, Lutterbüse R, et al. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 2000; 95:2098-2103.
20. Dreier T, Lorenczewski G, Brandl C, et al. Extremely potent, rapid and costimulation- independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer 2002; 100:690-697.
21. Schlereth B, Quadt C, Dreier T, et al. T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Cancer Immunol Immunother 2006; 55:503-514.
22. de Gast GC, van Houten AA, Haagen IA, et al. Clinical experience with CD3 - CD19 bispecific antibodies in patients with B cell malignancies. J Hematother 1995; 4:433-437.
23. Topp MS, Gö kbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: A multicentre, single-arm, phase 2 study. Lancet Oncol 2015; 16:57-66.
24. Topp MS, Gö kbuget N, Zugmaier G, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol 2014; 32:4134-4140.
25. Chichili GR, Huang L, Li H, et al. A CD3 - CD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates. Sci Transl Med 2015; 7:289ra82.
26. Schuster FR, Stanglmaier M, Woessmann W, et al. Immunotherapy with the trifunctional anti-CD20 - Anti-CD3 antibody FBTA05 (Lymphomun) in paediatric high-risk patients with recurrent CD20-positive B cell malignancies. Br J Haematol 2015; 169:90-102.
27. Rothe A, Sasse S, Topp MS, et al. A phase 1 study of the bispecific anti- CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood 2015; 125:4024-4031.
28. Eisenhut M, Lehmann WD, Becker W, et al. Bifunctional NHS-BAT ester for antibody conjugation and stable technetium-99m labeling: conjugation chemistry, immunoreactivity and kit formulation. J Nucl Med 1996; 37:362-370.
29. Diermeier-Daucher S, Ortmann O, Buchholz S, et al. Trifunctional antibody ertumaxomab: nonimmunological effects on Her2 receptor activity and downstream signaling. MAbs 2012; 4:614-622.
30. Cioffi M, Dorado J, Baeuerle PA, Heeschen C, et al. EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin Cancer Res 2012; 18:465-474.
31. Mau-Sørensen M, Dittrich C, Dienstmann R, et al. A phase I trial of intravenous catumaxomab: A bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3. Cancer Chemother Pharmacol 2015; 75:1065-1073.
32. Kroesen BJ, Nieken J, Sleijfer DT, et al. Approaches to lung cancer treatment using the CD3 - EGP-2-directed bispecific monoclonal antibody BIS-1. Cancer Immunol Immunother 1997; 45 (3-4):203-206.
33. Fury MG, Lipton A, Smith KM, et al. A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors. Cancer Immunol Immunother 2008; 57:155-163.
34. Grosse-Hovest L, Hartlapp I, Marwan W, et al. A recombinant bispecific single-chain antibody induces targeted, supra-agonistic CD28-stimulation and tumor cell killing. Eur J Immunol 2003; 33:1334-1340.
35. Titus JA, Perez P, Kaubisch A, et al. Human K/natural killer cells targeted with hetero-cross-linked antibodies specifically lyse tumor cells in vitro and prevent tumor growth in vivo. J Immunol 1987; 139:3153-3158.
36. Segal DM, Garrido MA, Perez P, et al. Targeted cytotoxic cells as a novel form of cancer immunotherapy. Mol Immunol 1988; 25:1099-1103.
37. Renner C, Held G, Ohnesorge S, et al. Role of perforin, granzymes and the proliferative state of the target cells in apoptosis and necrosis mediated by bispecific-antibody-activated cytotoxic T cells. Cancer Immunol Immunother 1997; 44:70-76.
38. Gall JM, Davol PA, Grabert RC, et al. T cells armed with anti-CD3 - Anti- CD20 bispecific antibody enhance killing of CD20 malignant B cells and bypass complement-mediated rituximab resistance in vitro. Exp Hematol 2005; 33:452-459.
39. Thakur A, Sorenson C, Norkina O, et al. Activated T cells from umbilical cord blood armed with anti-CD3 - Anti-CD20 bispecific antibody mediate specific cytotoxicity against CD20 targets with minimal allogeneic reactivity: A strategy for providing antitumor effects after cord blood transplants. Transfusion 2012; 52:63-75.
40. Zitron IM, Thakur A, Norkina O, et al. Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies. BMC Cancer 2013; 13:83.
41. Yankelevich M, Kondadasula SV, Thakur A, et al. Anti-CD3 - Anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets. Pediatr Blood Cancer 2012; 59:1198-1205.
42. Davol PA, Smith JA, Kouttab N, et al. Anti-CD3 x anti-HER2 bispecific antibody effectively redirects armed T cells to inhibit tumor development and growth in hormone-refractory prostate cancer-bearing severe combined immunodeficient beige mice. Clin Prostate Cancer 2004; 3:112-121.
43. Chan JK, Hamilton CA, Cheung MK, et al. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: A preclinical study. Clin Cancer Res 2006; 12:1859-1867.
44. Nitta T, Sato K, Yagita H, et al. Preliminary trial of specific targeting therapy against malignant glioma. Lancet 1990; 335:368-371.
45. Lamers CHJ, van de Griend RJ, Braakman E, et al. Optimization of culture conditions for activation and large-scale expansion of human T lymphocytes for bispecific antibody-directed cellular immunotherapy. Int J Cancer 1992; 51:973-979.
46. Canevari S, Stoter G, Arienti F, et al. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst 1995; 87:1463-1469.
47. Lamers CH, Bolhuis RL, Warnaar SO, et al. Local but no systemic immunomodulation by intraperitoneal treatment of advanced ovarian cancer with autologous T lymphocytes re-targeted by a bi-specific monoclonal antibody. Int J Cancer 1997; 73:211-219.
48. Lum LG, Thakur A, Pray C, et al. Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin's lymphoma: A pilot study. Bone Marrow Transplant 2014; 49:73-79.
49. Lum LG, Thakur A, Liu Q, et al. CD20-targeted T cells after stem cell transplantation for high risk and refractory non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2013; 19:925-933.
50. Lum LG, Thakur A, Al-Kadhimi Z, et al. Targeted T-cell therapy in stage IV breast cancer: A phase I clinical trial. Clin Cancer Res 2015; 21:2305-2314.
51. Korkaya H, Wicha MS. HER-2, notch, and breast cancer stem cells: Targeting an axis of evil. Clin Cancer Res 2009; 15:1845-1847.
52. Vaishampayan U, Thakur A, Rathore R, et al. Phase I study of anti-CD3 - Anti- Her2 bispecific antibody in metastatic castrate resistant prostate cancer patients. Prostate Cancer 2015; 2015:285193.
53. Alvarez-Vallina L, Hawkins RE, et al. Antigen-specific targeting of CD28- mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors. Eur J Immunol 1996; 26:2304-2309.
54. Renner C, Jung W, Sahin U, et al. The role of lymphocyte subsets and adhesion molecules in T cell-dependent cytotoxicity mediated by CD3 and CD28 bispecific monoclonal antibodies. Eur J Immunol 1995; 25:2027-2033.
55. McCall AM, Shahied L, Amoroso AR, et al. Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity. J Immunol 2001; 166:6112-6117.
56. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15:7412-7420.